| |
This two-part podcast series covers topics from compliance and Master Data Management, to HCP targeting and the value of a single database that connects digital channels and empowers sales teams. Don’t miss out, tune in now! 
|
|
|
Tuesday, April 23, 2024 | 1pm ET / 10am PT Join us as we dive into the pivotal challenges facing clinical trial enrollment today. Learn about innovative strategies and solutions for quickly identifying the right patients for specific therapies, the optimal time in their health journey to engage, and how to successfully activate them for trial enrollment. Register now. 
|
|
| By Gabrielle Masson The biotech industry has been holding its breath, hoping that 2024 would bring some reprieve from 2023’s brutal bear market. But market recovery is a slow process, and the number of layoffs reported this quarter reflect that sentiment, with 57 layoff rounds reported for the first three months—the exact number reported during the same period last year. |
|
|
|
By Zoey Becker While the drug is not listed on the FDA's shortage list, some pharmacies are facing supply issues. Amazon Pharmacy, for instance, notes that several dosage strengths are "unavailable." |
By Zoey Becker Four dose strengths are now expected to be in short supply through April, according to the FDA. The agency previously expected the squeeze to let up at the end of March. |
By Annalee Armstrong Days after Regeneron received a complete response letter for the blood cancer medicine odronextamab, hematology executive Andres Sirulnik says the trial is enrolling just fine—it’s just that randomization hasn’t begun. |
|
Wednesday, April 24, 2024 | 12:30pm ET / 9:30am PT It is more important than ever to leverage precision approaches for characterizing sub-populations of patients and uncovering genetic drivers of safety and response. Join expertsfor a look at the latest methods for identifying promising drug targets and biomarkers to advance therapeutic development and the application from research to clinical care. Register now. 
|
|
By Conor Hale 3M has finished carving out its healthcare business, formally establishing Solventum as an independent, St. Paul, Minnesota-based manufacturer of a medtech catalog that brought in $8.2 billion in 2023 sales. |
By Angus Liu Lonza’s search for a CEO has led the Swiss CDMO giant to its compatriot competitor, Siegfried. The appointment of Wolfgang Wienand could end a period of leadership instability marked by multiple CEO handovers since 2019. |
By Gabrielle Masson More than 60 years after RhoGAM’s approval, Johnson & Johnson's Katie Abouzahr, M.D., is hoping to build off the pharma’s own legacy and bring another maternal fetal immunology treatment to market. |
By Fraiser Kansteiner Like clockwork, AstraZeneca CEO Pascal Soriot’s pay is under fire again. The two most influential proxy advisory firms are rallying investors to vote against the 2024 pay proposal for Soriot at the company’s annual general meeting this month. |
By Nick Paul Taylor Pfizer is learning there is a kernel of truth in the saying “the internet never forgets.” More than three years after the offense, the drugmaker has received a telling-off from the U.K. drug promotion watchdog over a retweet by one of its employees. |
By Helen Floersh Researchers for the first time have identified dysfunctional immune cells in the healthy breast tissue of women with mutations in the genes BRCA1 and BRCA2, a finding that opens up the possibility of using existing immunotherapy drugs to prevent cancer before it forms. |
Fierce podcasts Don’t miss an episode |
| This week on "Podnosis," we explore the field of social prescribing and the role of arts and culture in shaping the future of mental health treatment. |
|
|---|
|
|
|
Available On-Demand Navigating the complexities of the rapidly evolving landscape of cell therapy manufacturing poses significant challenges. Access this discussion on-demand to learn more about the top challenges cell therapy developers are facing. We explore the need for closed, automated, and flexible manufacturing workflows that are designed to de-risk the process for clinical and commercial success. View now. 
|
|
Whitepaper This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Selecting a 3PL with a proven track record of delivering high-quality services is critical to a successful pharma supply chain. Here's how. BioCare |
Whitepaper Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
